Changchun, China – Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is a major global health concern with rising rates, particularly in North Africa and East Asia. Although potentially curable in the early stages, HCC often remains undetected until it’s too late for effective treatment. This...
research News
Palo Alto, Calif. – Using novel machine learning tools developed at Stanford Medicine, researchers have mapped three distinct cellular configurations that correspond to clinical outcomes for patients with a rare, difficult-to-treat cancer called soft tissue sarcoma. In particular, the technique identified a cellular neighborhood that correlated with a positive response...
SINGAPORE – Rare diseases affect fewer than 1 in 2,000 people individually. However, with over 7,000 different types identified, their global impact is significant. In the Asia-Pacific region, approximately 258 million people have a rare disease, the highest number globally, with over 45 million in Southeast Asia alone. This vast...
SEOUL, South Korea — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of six studies at the upcoming SITC (Society for Immunotherapy of Cancer) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California. During this year’s...
OCALA, Fla. — AIM ImmunoTech Inc., today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”). Data strongly suggests...
Rockville, MD – AIM-HI Accelerator Fund is proud to celebrate a significant milestone in the journey of one of its esteemed portfolio companies, Yiviva. A clinical-stage platform biotechnology company, Yiviva has entered into a Memorandum of Understanding (MOU) with AstraZeneca China, a multinational biopharmaceutical leader. AIM-HI was established with a...
HONG KONG — Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS＜1%) non-small cell lung cancer (NSCLC)...
HONG KONG — Akeso, Inc. today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mid- and advanced-stage hepatocellular carcinoma (HCC) in a poster at the 2024 American Society of Clinical Oncology...
HONG KONG — Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting. HR-MDS Anemia...
ATLANTA, GA — Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety...